Aims and background: Improved visualization of surgical targets inside of the patient helps to improve radical resection of the tumor while sparing healthy surrounding tissue. In order to achieve an image, optical contrast must be generated by properties intrinsic to the tissue, or require the attachment of special visualization labels to the tumor. In this overview the current status of the clinical use of fluorescent dyes and probes are reviewed.
Introduction
The principles of cancer treatment are radical resection of the primary tumor, with or without its metastases and its draining lymph nodes. In the earlier days, the resections were extensive, but current practice emphasizes sparing healthy tissue as much as possible. Better visualization of surgical targets inside of the patient helps to improve radical resection of the tumor while sparing healthy surrounding tissue. Tumor boundaries are not easily discriminated and their sentinel lymph nodes can be difficult to detect. Improvement of visualization in a non-invasive manner is possible by the use of optical imaging. Optical imaging is defined as a technique that exploits the properties of light emitted from a laser or infrared source to image anatomic or chemical properties of matter. In order to achieve an image, optical contrast must be generated by properties intrinsic to the tissue, or require the attachment of special visualization labels to the tumor. The latter approach, exploiting the luminescence generated by these specific labels, is most commonly used. At this moment there are three major types of labels used in optical imaging: fluorescent proteins, bioluminescence, and fluorescent dyes. 1 Whereas bioluminescence and fluorescent proteins need engineering of cell lines or transgenic animals that carry the appropriate gene, fluorescent dyes do not, and may be unspecifically or specifically targeted to the relevant tissue. This property gives fluorescent dyes the potential for more rapid translation to clinical applications than approaches requiring genetic engineering. In this overview we discuss the current status of the clinical use of these fluorescent dyes.
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Methods
A search of Medline and Pubmed databases of studies on fluorescent imaging was performed.
All studies were included in this review, in order to give an accurate overview of the current status of the use of fluorescence in tumour models as well as clinical applications. A division was made into imaging of surgical anatomy by Indocyanine Green, dyes and probes that accumulate in the sentinel lymph node, probes that visualize increased cell-metabolism, probes that are activated by tumor-associated proteases and probes that bind to a specific molecular target. In the search for the optimal fluorescent imaging modality, at first, a summary was given to describe the characteristics of a fluorescent dye.
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Fluorescent Dye Characteristics
For an optimal image, the fluorescent dye needs to fulfill several criteria with respect to the following characteristics: wavelength, quantum yield, solubility, photobleaching, non-specific binding, signal-to background ratio, clearance and toxicity.
Wavelength: Firstly, fluorescent light needs to propagate a maximum distance through the tissue. Limiting factors for the depth of tissue penetration are absorption and scattering of light; 2 with increasing wavelength (that is in the red or infrared region of the optical spectrum) absorption and scattering of light in tissue decreases. Fluorescent dyes can be designed to emit at a range of different wavelengths spanning the optical spectrum. Below ~700 nm the wavelength of the fluorescent dye is too low to be detected further than a few hundreds of micrometers of tissue penetration. 2 Between 700 nm and 900 nm (the near-infrared region, NIR) absorption is at its lowest. Usage of dyes with wavelengths above 900 nm is not possible because water absorbs very strongly at these wavelengths, dramatically reducing the efficacy of light transmission. 3 In order to maximize the depth of tissue penetration, the most optimal wavelengths for fluorescent dyes used in tissue imaging applications is between 700 and 900nm. 3 Another requirement of optimal fluorescence imaging is to minimize interference from intrinsic fluorescence (often termed autofluorescence) from the patient's tissue. NIR fluorescent dyes are not hindered by interfering autofluorescence because the patient's tissue generally exhibits negligible emission in this region.
1,4
Quantum Yield: Another criterion is that the dye should possess a high quantum yield. The fluorescence quantum yield (QY) reflects the efficiency of the fluorescence process. The QY is defined as the ratio of the number of photons emitted to the number of photons absorbed.
The maximum fluorescence QY is 1.0 (100%); every photon absorbed results in a photon Solubility: It is evident that the dye needs to be soluble for administration into the tissue whether intravascular or into the lymph stream.
Photobleaching: Photobleaching is the photochemical destruction of a fluorophore and may complicate the observation of fluorescent molecules as they will eventually be destroyed by the light exposure (named fluence) necessary to stimulate them into fluorescing. The lower the photo bleaching of the dye, the higher the stability and its potential for practical use.
Non-specific binding:
Obviously non-specific binding of the dye should not occur or should only be very minimal. 5 Non-specific binding may occur with cellular membranes, proteins and extra cellular matrix materials. Such non-specific binding results in background fluorescence, which reduces the signal-to-noise ratio and limits tagging specificity and detection sensitivity.
Signal to background ratio:
The criteria mentioned above (Wavelength, Quantum Yield, Solubility, Photo bleaching and Non-Specific Binding) all influence the signal-to-background ratio, a quantity that should as high as possible for optimal detection of the fluorescent dye.
Clearance and toxicity: Apart from the physical properties of the dye, practical use of the agent is determined by its toxicity. The clearance of free dyes is one of the parameters for toxicity. Besides, it is also a parameter influencing interfering-background light, as any uncleared free dye will contribute to the background. The optimal dyes should, therefore, have a rapid clearance. 
Wavelength
All the dyes have wavelengths between 700-900 nm, except for Cy5.5, that has a emission wavelength of 695 nm. 1 Therefore, Cy5.5 might be influenced by some auto fluorescence.
The separation between excitation and emission wavelengths, also known as the Stokes' shift, for all the above-mentioned dyes is large enough to enable efficient filtering of the emitted fluorescence from the excitation light. QDs have an exceedingly excitation or absorption spectrum, and are efficiently excited by excitation wavelengths lower than their emission wavelength. 6 QD's of the same material, but with different sizes, can emit light of different colors, enabling efficient multiplexed imaging of several different QDs with the same excitation wavelength.
Quantum Yield
Each of the dyes considered here possesses a quantum yield above the minimum value of 0.10. However, there is a considerable range in the quantum yields of the dyes. ICG and Irdye800 CW have the lowest QY (respectively 0.13 and 0.15) 7 , followed by Cy5.5 and Cy7
(respectively 0.25 and 0.27). The QDs have the highest QY (0.50-0.60), making them highly fluorescent. 4 The quantum yield of ProSense 750 is difficult to measure since it is a quenched dye and is activated only on cleavage. However, its yield is comparable to the industry standard of Cy7.
Aqueous Solubility
ICG, being a disulfonate, is only moderately soluble, however, it can still successfully be administered intravenously (as reviewed in Frangioni 2003) . 4 All other cyanines have a good aqueous solubility. 8 The QDs have different aqueous solubility. The first developed QDs had an outer shell that rendered these QDs insoluble. New QDs have improved as they now have an aqueous-compatible organic layer.
Photo Bleaching
All conventional fluorophores are sensitive to photo bleaching, which limits the emitted light or fluence rate to ~ 50 mW/cm 2 . 9 This rate is sufficient to permit efficient optical imaging. In contrast, QDs are resistant to photo bleaching, so that fluence rates can be much higher than 50 mW/cm 2 . However, at higher fluence rates tissue damage can occur.
Non-Specific Binding
Non specific binding contributes to the background and not to the signal, decreasing the signal to background ratio. Most cyanines have a low non-specific binding. 4 However, ICG is a cyanine with a high affinity for protein, causing a high non-specific binding to proteins. 4 Many older QDs have charged surface groups and, therefore, have a high non-specific binding. 10 QDs are actively researched and continually developed. Recent research indicates that hydroxyl-coated QDs have a 140-fold reduction in non-specific binding relative to that of carboxylated QDs and a 10-20-fold reduction to that of previous generation QDs. 5 This results in a lower non-specific binding for the new QD`s. ProSense 750, being an activator and not a binder, is not influenced by non-specific binding.
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Signal to Background Ratio
The criteria mentioned above form the signal in the signal-to-background ratio. ICG scores the lowest at the previous criteria and has, therefore, the lowest ratio while QDs have the highest ratio. The signal-to-background ratio of ProSense 750 is high because the background is nil, as it is only fluorescent when activated.
11
Clearance of Free Dyes
ICG and the other free cyanines are rapidly cleared from the blood. 
Toxicity
ICG has a remarkably good safety record and is the only FDA approved fluorescent dye. 12 Side effects are very low and generally very mild. 13 The toxicity of Cy5.5 is not completely evaluated. Comparative cytotoxic studies in vitro, however, indicate that the toxicity of Cy5.5
is even less than that of ICG. 14 Unpublished animal studies showed no specific toxicity of the one of the latest cyanines Irdye800 CW. For ProSense 750, phase 1 studies are in progress (data from manufacturer). The toxicological properties have not been investigated thoroughly yet. QDs have characteristics that could render them potentially dangerous. 15 One of them is the low renal clearance. The other is that QDs contain metals that, in their elemental forms, are toxic. 4 Especially the potential toxicity of cadmium or selenium containing QDs remains a major problem for human use. 
Imaging of Surgical Anatomy by Indocyanine Green
Indocyanine green (ICG) has been used for vascular mapping [16] [17] [18] , angiograms of the eye 19, 20 and angiograms of the brain 21, 22 . In oncology, identification of hepatic segments and subsegments for facilitation of hepatic resection was performed in 35 patients with malignant liver disease. 23 The real-time imaging technique proved to be safe and reproducible. ICG was injected into the patient's portal vein branch and images were produced with a special camera. 
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Dyes and Probes That Accumulate in the Sentinel Lymph Node
The SLN is the first lymph node that receives lymphatic drainage from a solid tumor. If in the examination of the SLN no malignant cells are detected, lymphatic metastases can be excluded. 24 In several cancers, such as breast cancer and to a lesser extent melanoma, detection of the SLN has become the clinical standard. For mapping the entire lymphatics, a probe should be small enough so that it can spread through the lymph nodes and image all the small branches. In contrast, to identify and map the Sentinel Lymph Node (SLN) the dye should be large enough to be retained inside the lymph nodes.
The current procedure of SLN mapping is performed with a combination of preoperative nanocolloid injection and intra-operative injection of methylene blue. 25 Although mostly very accurate, unfortunately there are still some disadvantages of the currently-used procedure. The use of the tracer can be logistically complicated when administered a day before the operation by a nuclear medicine physician. It exposes patient and caregivers to a very low amount of ionizing radiation. In addition, the real time imaging with methylene blue is not always very sensitive. 26 It can also result in false-positive nodes because the small dye particles can be readily diffused through the true SLN and traverse multiple nodes. 27 The blue dye does not have optimal tissue contrast. 28 Most important, the blue dye when injected into the dermis colors the skin of the patient for several months.
Fluorescent dyes and probes can be used for mapping of the SLN and some authors claim that it can eliminate the need of radioactive tracers and blue dye. 29 For successful application of fluorescent dyes or probes, three features are important: median hydrodynamic diameter, absence of surface charge, and high contrast generation. 7 In the paragraphs below the different dyes and probes and their modes of functioning are discussed.
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Dyes
The feasibility of ICG for lymphatic imaging was already demonstrated in several animal studies. Ogata et al. detected superficial lymphatic vessels in a rat model with a minimal diameter of 0.1 mm. 13 The sensitivity of detecting vessels seems to be almost 100% since they identified ICG fluorescence from lymphatic vessels in all of the examined animals. The ICG remained inside the lymphatic vessels for at least ten minutes. The specificity is presumed to be 100% because when ICG is injected into arteries or veins instead of the lymphatics, the dye is immediately washed away within a minute, causing immediate blurring and disappearance of the fluorescence.
The first use of ICG in human SLN mapping was done by Motomura et al. (1999) . 30 The SLN biopsy was guided by ICG in 172 patients with stage I or II breast cancer. The ICG was injected into the breast parenchyma surrounding the primary tumor. However, the SLNs were resected without the use of NIR light due to the lack of a special camera and were identified by eye. Thus, SLNs were only identified in 127 of 172 patients (73,8%) with a false-negative rate of 11.1%, defined as a negative SLN with positive lymph nodes in the axillary dissection specimen.
Dissection of the fluorescent SLN by fluorescence navigation was initiated by Kitai et al. (2005) . 31 The images were obtained by a prototype charge-coupled device (CCD) camera surrounded with LEDs that emitted light at a wavelength of 760 nm. Eighteen patients with stage I or II breast cancer were injected subcutaneously around the areola with ICG.
Visualization of nodes without the camera was successful in 50% of the patients, whereas the use of the imaging system increased the identification rate to 94%. These authors did not report false-negative SLN's.
In 2008, Tagaya et al. mapped the SLN with ICG and used a blue dye (indigo carmine) as a control. 32 The dyes were injected subdermally at the same time around the areola. The image M A N U S C R I P T
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13 was produced by a more sophisticated camera, the Photodynamic Eye (PDE, Hamamatsu Photonics, Hamamatsu, Japan.). The SLNs were detected under fluorescence guidance in all 25 patients, resulting in a detection rate of 100% without false negative nodes and without any need for training. The control group using blue dye only detected lymph nodes in 92% with a false negative percentage of 11.8. Lowering the dose of ICG in this model was found by others to lead to lower efficacy. 33 Interestingly, in a study on lymphatic drainage the network could be observed in 89.2% of all patients, however in the tumor area, only in 12 of 33 patients could lymphatic pathways be observed. 34 Although this observation may deepen the apprehension of lymphatic drainage of the tumour in general, it may not be clinically relevant for detection and resection of the SLN(s).
In a small series of ten skin cancer patients, ICG fluorescence guided by PDE was successfully used to map the SLNs in all ten patients. 35 In this study, the SLNs remained fluorescent for over three hours.
In gastric cancer SLNs were detected by ICG and PDE in 90.9% and colorectal cancer in 88.5% of monitored patients. 36 However, in these patients very high false negative rates were found (70.0 % for gastric cancer and 66.7% for colorectal cancer), since many of the detected lymph nodes were not the true SLN. The accuracy of SLN detection for patients with T1 stage colorectal cancer as well T1 stage gastric cancer was better than for the higher staged tumors.
In three T1 gastric cancer patients, SLNs were detected by ICG fluorescence imaging in all cases even though the dye was injected a day before the surgery.
37
In rectal cancer the detection rate of the SLN appeared to be very low; only in seven out of 25 patients (28%) could the SLN be detected. 
Probes
The detection time of ICG used as an individual dye in the above mentioned studies differs from several minutes to a day before surgery. 7, 37 To increase the detection time, ICG can be conjugated to Human Serum Albumin (HSA). HSA exhibits a long blood half-life and, therefore shows lymphatic accumulation. 39 When injected in melanomas, the ICG:HSA probe conjugate identifies the SLN's and their associated lymphatic channels in less than a minute.
29
A newer conjugate with HSA, the fluorescent dye HSA800 has been tested in pigs' in hind legs and an esophageal SLN model and provided a twofold higher fluorescent yield than earlier conjugates, demonstrating even the ultra-fine lymphatics. 7, 40 Recently, the first human trial in six women with breast cancer was performed using ICG:
HSA. 8 of 9 SLNs identified by Tc-99m sulfur colloid were also identified by fluorescence.
Furthermore, fluorescence identified an SLN, confirmed to have cancer in it, that was not identified by Tc-99m sulfur colloid (figure 1). 41 By combining two fluorescent dyes with different wavelengths, i.e. Cy5.5 and Cy7, coupled to immunoglobulin G in postmortem athymic mice multicolor visualization of lymphatics has been demonstrated. 42 By labeling different pathways of lymphatics, theoretically disruption of the lymphatics of normal organs can be avoided and thereby reduction of lymphedema can be achieved.
Furthermore, dyes as Cy5.5 have been conjugated to a protected graft copolymer (PGC). 43 PGC is a macromolecule, that when administered intravenously has a long blood half-life and collects in lymph nodes. This could be of help during minimally invasive procedures, since there is no need for peri-tumoral injection.
In theory, the use of QDs for detection of SLNs yields optimal performance. Because of their large diameter the retention in the SLN of QDs is 100%. In addition, their contrast is very high, in multicolor and without fading due to photobleaching. 29, 44, 45 Furthermore, there is M A N U S C R I P T
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15 no need for conjugation. However, as mentioned before, QDs have unknown toxicity and are composed of potentially toxic metals, thus lacking current potential for clinical application. 15 In rats as well as pigs, one research group has studied lymphatic mapping in skin, esophagus, lung, gastro-intestinal tract, pleural pace, peritoneal space, limb, and mammary tissue.
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Probes That Image Increased Cell-Metabolism
Optical imaging can also exploit probes that image increased glucose metabolism of the tumor. Tumor cells often have an increased glucose metabolism due to their preferential use of glycolysis for energy generation and to the overexpression of glucose transporters (GLUTs). 46 The most commonly used agent to measure increased glucose metabolism is 2-
deoxy-2-[
18 F]fluoro-D-glucose which is widely used in tumor diagnosis, staging, and monitoring therapeutic response. 47, 48 The imaging is done by the use of positron emission tomography (PET). 47 However, PET scanning cannot be used real-time and spatial resolution is relatively low. For optical imaging, two NIR deoxyglucose analogues have been synthesized and will be discussed below.
The first deoxyglucose analogue is Pyro-2DG. The fluorescent moeity that was used for Pyro-2DG is pyropheophorbide and emits in the NIR wavelength range. The probe is accumulated in the tumor through the GLUTs and thereafter retained in the tumor by phosphorylation by hexokinase. Zhang et al. (2004) have found in the glioma bearing rat model as well as in MTB/TOM bitransgenic mice that Pyro-2DG selectively accumulates in the tumor compared to surrounding normal tissue at a ratio of 10:1. 49 Since there is a high discriminative potential, mapping with a high signal-to-noise ratio in that study was possible.
Coupled to Cy5.5 the tumor-targeting ability of the deoxyglucose analogue 2DG was tested in cell cultures as well as in glioblastoma bearing nude mice. 47 The 2DG-Cy5.5 did accumulate in tumor cells, although GLUTs were not the responsible transporter in this M A N U S C R I P T
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16 model, and the mechanism of accumulation remained unresolved. The fluorescent Cy5.5 appeared to be too large to be trapped by the GLUTs and therefore it cannot be used as a marker for GLUTs over-expression.
Probes That Are Activated by Tumor-Associated Proteases
Many tumors are known to have increased levels of proteolytic enzymes. 50 These tumorassociated proteases function at multiple stages, affecting tumor establishment, growth, angiogenesis, intravasation, extravasasion, and metastasis.
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Probes designed to be solely activated by a specific protease in theory are tumor specific.
Only after interaction with the proteases do the probes become fluorescent. Three probes have been designed so far by one research group and they are all activated by protease Cathepsin B. [51] [52] [53] [54] [55] [56] This protease is known to be up-regulated in areas of inflammation, necrosis, angiogenesis and focal invasion. 57 Being optically silent when injected, the probes have a low background signal which results in higher signal-to-background ratios when compared to nonspecific probes.
For this approach Cy5.5 can be bound to a long circulating and large protected graft copolymer (PGC) in such a way that cleavage of this binding is induced by the tumor protease Cathepsin B. 43 In breast carcinomas and LX-1 small cell carcinomas of nude mice, cleavage of Cy5.5 from the PGC leads to a 12 fold increase in NIR fluorescence signal. 51 In 2002, Cy5.5-PGC-Cathepsin B imaging was used to discriminate adenomatous polyps in APC-mice from normal mucosa. 53 This study provided opportunities for selective removal of polyps, thereby reducing the transformation of polyps to colorectal cancer. 53 More recent probes using this concept are the ProSense 680 and 750 dyes (Visen medical).
The process of cleavage is identical to Cy5.5-PGC. ProSense consists of graft copolymers coupled to quenched fluorochromes that are released after Cathepsin B cleavage. In mice,
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17 selective tumor imaging can be obtained by ProSense 680 imaging of Cathepsin B expressing lung tumors. 54 The tumoral protease activity was used to improve the detection of small peripheral lung cancer in the Lewis Lung Carcinoma model by use of a novel ProSense 750. 55 In this study, the imaging was performed by NIR microcatheters during thoracoscopy.
ProSense 750 was also used in combination with a hand-held imaging device to detect residual sarcoma tissue during surgery in mice. 56 In addition, in combination with fluorescence tomography, it enabled visualization of lung metastasis of the resected sarcomas.
Due to its sensitivity, molecular specificity, favorable pharmacokinetics and lack of toxicity, ProSense 750 emerges as a promising clinical imaging agent. 8 Until now, however, these probes have only been tested in animal-studies, while Phase I clinical trials are planned to begin in 2009.
The third and last fluorophore, Chlorin e6 (Ce6), is again quenched to PGC. 58 It accumulates in the tumor and is selectively activated by Cathepsin B. Ce6 is a photodynamic agent and in theory can, apart from imaging, be used for therapeutic purposes as well. When it is illuminated by an appropriate wavelength it transfers its energy to a neighboring molecular oxygen, producing cytotoxic singlet oxygen which causes selective tissue damage, the fundamental principle of photodynamic therapy. 58 In mice bearing fibrosarcomas on the hind limb, protease-mediated photodynamic therapy selectively suppressed tumor growth by >50%. When Ce6 is used on its own, it is not very selective, and may cause damage to normal cells as well.
Probes That Bind to a Specific Molecular Target
Besides proteases, there are many more molecules that are preferentially expressed in malignant cells compared to normal cells. Fluorescent dyes conjugated to specific binders can be used to image these tumor specific targets.
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18 Chlorotoxin (CTX) is a small peptide isolated from scorpion venom that binds specifically to gliomas and related cancers. 59 The receptor for chlorotoxin on glioma cells is matrixmetalloproteinase-2 (MMP-2), which is not expressed in normal brain. 59 In phase I clinical trials for human brain cancer therapy TM-601, the synthetic version of chlorotoxin, was tested and no dose-limiting toxicities were observed. 60 Veiseh et al (2007) coupled CTX to Cy5.5 at doses used for optical imaging in several xenograft mice models without detecting any toxicity. 61 They concluded that CTX:Cy5. The effective use of fluorescent antibodies to visualize antigens was demonstrated already in 1995. 62 Ballou et al conjugated several antibodies to cyanines in teratocarcinoma and melanoma mice. 61 A more recent article from Liu et al 63 reports conjugation of transferrin and a mouse anti-human CD74 monoclonal antibody to QDs. These constructs were highly specific to tumor cells in vitro.
Integrins are proteins that function as a receptor and play a role in tumor progression, angiogenesis, and metastasis. 64 Integrin αvβ3 is expressed by newly formed tumor microvessels but not by preexisting vessels or by blood vessels in non-neoplastic tissues. 64 Integrin αvβ3 binds peptides that contain the amino acid sequence Arg-Gly-Asp (RGD).
Radio labeled-RGD has been used to measure integrin αvβ3 expression. Wang et. al. (2004) successfully used the integrin αvβ3-targeted peptide c(KRGDf) labeled with Cy5.5 and Irdye800 to detect Kaposi sarcomas and melanomas in nude mice . 65 Instead of cyanines, Cai et al. (2005) used QDs as a NIR label. 66 QDs linked to RGD peptides were tested in a mouse M A N U S C R I P T
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19 ear tumor model. 67 The purpose of this research was to study the QD's function, helping to ensure regulatory approval of nanoparticles in humans. The QDs did not extravasate and showed selective binding to single cells of tumor neovasculature. Another fluorochrome that was conjugated to RGD peptides is Cy7. 68 In this study the level of integrin expression was used to evaluate anti-integrin therapy. Cy7 proved to have a deeper tissue penetration then Cy5.5. Cy5.5, however, was retained longer in tumor tissue.
In addition, anti-epidermal growth factor receptor (EGFR) antibodies have been conjugated to QDs. EGFR plays an important role in tumor growth and is associated with a more aggressive disease and shortened survival in cancer patients. 69 Green 488 (OG) was used to visualize colorectal tumors in SCID mice. In this study a heterogeneous binding pattern to EGFR expressing tumors was observed. 71 There was a mismatch of Cetuximab:OG uptake in relation to the extent of EGFR expression that might be explained by the tumor's vascularization and necrosis. Gleysteen et al. conjugated Cetuximab to Cy5.5 and used it in SCID mice in a pulmonary metastatic model as well as a model of regional head and neck metastases. 72 In this study, the fluorescence was successfully confirmed by histopathology in all mice.
Other studies focused on HER-2 receptor binding. The HER-2 receptor is a member of EGFR family and plays a role in tumor growth and prognosis. Herceptin. These probes appeared to be non toxic for HER-2 overexpressing cells.
Considerations for Future Use
At present many effective fluorescent dyes are available within the NIR spectrum. Table 1 . The following characteristics of fluorescent dyes are compared: wavelength, quantum yield, solubility, photo bleaching, non-specific binding, signal-to background ratio, clearance and toxicity.
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